Lasa Supergenerics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Thu Apr 23 2026

Lasa Supergenerics (LASA) is set to announce its Q4 FY26 results in May 2026. Investors and market participants are keenly watching the upcoming quarterly numbers for one of India’s well-known Pharmaceuticals and Biotech companies. The Q4 FY26 earnings season is a critical period for equity markets as full-year financial performance comes into sharper focus.

Analyst consensus estimates project Lasa Supergenerics Q4 FY26 revenue at Rs 74 Cr, representing a year-on-year growth of approximately 9%, while PAT is estimated at Rs 8 Cr, a growth of approximately 33% compared to the same quarter in FY25. These estimates reflect the sector outlook and company-specific operational momentum observed over the preceding quarters.

In this article, we provide a detailed preview of Lasa Supergenerics Q4 results 2026, including the expected date, key financial estimates, five growth factors, five risks and the latest analyst ratings. Get free investment insights on Univest to stay ahead of earnings season.

Table of Contents

Lasa Supergenerics Q4 Results 2026 Date

Access premium research and earnings previews on Univest before every major result announcement.

The Lasa Supergenerics Q4 FY26 results are expected to be declared in May 2026. The board of directors will convene a meeting to approve the audited financial results for the quarter and full year ended March 31, 2026. The exact date will be intimated through BSE and NSE filings. Investors should monitor exchange announcements for the confirmed date.

Company	Q4 Results Date	Key Watch
TCS	April 9, 2026	Revenue growth and deal wins
Infosys	April 23, 2026	FY27 guidance and margin outlook
Lasa Supergenerics	May 2026 (Expected)	Revenue, PAT and dividend announcement

Why This Quarter Matters for Lasa Supergenerics

The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.

For Lasa Supergenerics specifically, Q4 FY26 is a critical quarter as it determines the full-year FY26 performance trajectory. The management’s commentary on FY27 outlook, any guidance revision and dividend announcement will be equally important for investor sentiment as the headline revenue and PAT numbers.

Lasa Supergenerics Q4 FY26 Earnings Estimates

Screen Lasa Supergenerics fundamentals, historical financials and technical indicators on Univest Screener.

Based on analyst consensus and sector-level research, Lasa Supergenerics is expected to report Q4 FY26 revenue of Rs 74 Cr, up 9% year-on-year. PAT is estimated at Rs 8 Cr, reflecting 33% growth. EBITDA margin is expected to come in at approximately 10.8%, showing improvement compared to the year-ago quarter driven by operating leverage and cost efficiencies.

Metric	Q3 FY26 (Actual)	Q4 FY26 (Estimate)	YoY Change
Revenue (Rs Cr)	68	74	+9% (Est)
PAT (Rs Cr)	6	8	+33% (Est)
PAT Margin (%)	8.8%	10.8%	Expanding
Dividend History	Nil		–
Dividend Expectation	Nil expected		–

Beyond the headline numbers, key metrics to watch include EBITDA margin trajectory, working capital management, order book or pipeline commentary and management guidance for FY27. These forward-looking indicators often have a larger impact on stock price reaction than the reported PAT figure alone.

Track Lasa Supergenerics fundamentals and compare it with sector peers on Univest Screener for in-depth financial analysis.

5 Key Factors That Will Drive Lasa Supergenerics Q4 FY26 Performance

1. US Generics Business Recovery

Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.

2. Domestic Formulations Growth

India’s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.

3. API Segment Expansion via China Plus One

China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.

4. Complex Generics and Biosimilars Pipeline

Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.

5. Emerging Market Revenue Diversification

Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.

5 Risks to Watch in Lasa Supergenerics Q4 FY26

1. USFDA Inspection and Import Alert Risk

USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.

2. US Generics Price Erosion

Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.

3. Raw Material Cost Pressure

API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.

4. DPCO Price Control Impact

Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.

5. Currency Risk on Export Revenues

Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.

Lasa Supergenerics Share Price and Analyst Ratings

Lasa Supergenerics (LASA) is currently trading at Rs 145 with a market capitalisation of approximately Rs 485 Cr. The stock has been under investor scrutiny ahead of Q4 results, with analysts closely monitoring sector trends and company-specific developments that could influence the quarterly outcome.

Brokerage	Rating	Target Price	Thesis
Bernstein	Outperform	Rs 171	US generics recovery and complex pipeline launches
CLSA	Buy	Rs 171	Domestic growth and API China Plus One opportunity
JM Financial	Buy	Rs 171	Margin expansion and emerging market revenue growth

Download the Univest iOS App or the Univest Android App to track Lasa Supergenerics share price, analyst ratings and earnings updates in real time.

Conclusion

Lasa Supergenerics heads into Q4 FY26 with reasonable earnings visibility, supported by sector tailwinds and company-specific operational improvements. The Q4 numbers will be an important validation of the full-year FY26 investment thesis. Investors should track the results date, dividend announcement and management commentary on FY27 guidance closely. For ongoing research and stock insights, visit Univest Blogs.

This article is for informational and educational purposes only and does not constitute investment advice. All estimates are based on publicly available analyst research and are subject to change. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

What is the Lasa Supergenerics Q4 results 2026 date?

The Lasa Supergenerics Q4 FY26 results are expected to be announced in May 2026. The exact date will be confirmed by the company’s board through a BSE and NSE filing. Check Univest for real-time updates.

What is the Lasa Supergenerics Q4 FY26 PAT estimate?

Analyst consensus estimates put Lasa Supergenerics Q4 FY26 PAT at approximately Rs 8 Cr, representing a year-on-year growth of approximately 33% compared to the same quarter in FY25. These are estimates and actual results may vary.

What is Lasa Supergenerics share price ahead of Q4 results?

Lasa Supergenerics share price (ticker: LASA) is trading near Rs 145 with a market capitalisation of approximately Rs 485 Cr. Investors should track the stock on Univest Screener for live price and fundamental data.

Will Lasa Supergenerics declare a dividend in Q4 2026?

Based on available analyst estimates and historical dividend patterns, Nil expected. Lasa Supergenerics’s historical dividend record shows Nil. A final dividend announcement is typically made at the board meeting where Q4 results are declared.

Which analysts have a Buy rating on Lasa Supergenerics?

Based on publicly available brokerage research, Bernstein has a Outperform rating on Lasa Supergenerics with the thesis: US generics recovery and complex pipeline launches. Ratings are subject to change; always consult a SEBI-registered advisor before investing.

What were Lasa Supergenerics Q3 FY26 results?

Lasa Supergenerics reported Q3 FY26 revenue of Rs 68 Cr and PAT of Rs 6 Cr. The management commentary highlighted key operational metrics and sector-specific guidance that set the expectations benchmark for Q4 FY26 performance.

When do Infosys and TCS announce Q4 results 2026?

TCS announced its Q4 FY26 results on April 9, 2026, while Infosys announced on April 23, 2026. These results set the broader IT sector tone and benchmark for Q4 earnings season.

Is Lasa Supergenerics a good investment ahead of Q4 results?

Lasa Supergenerics operates in the Pharmaceuticals and Biotech sector and its Q4 FY26 performance will be determined by the factors outlined above. Any investment decision should be based on your personal financial goals, risk tolerance and a consultation with a SEBI-registered investment advisor. Access research on Univest.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE and BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.